Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib
about
PC3 prostate tumor-initiating cells with molecular profile FAM65Bhigh/MFI2low/LEF1low increase tumor angiogenesisCombinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current statusAxitinib Improves Radiotherapy in Murine Xenograft Lung Tumors.Mannan-modified adenovirus targeting TERT and VEGFR-2: A universal tumour vaccine.Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantroneThrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis.Quantitative imaging of gold nanoparticle distribution in a tumor-bearing mouse using benchtop x-ray fluorescence computed tomography.Efficacy of combined axitinib with dacarbazine in a B16F1 melanoma xenograft modelImpact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor model.Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours.Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?Recent advances in anti-angiogenic therapy of cancerAngiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales.VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression.Antiangiogenesis enhances intratumoral drug retention.Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo.A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells.CT spectral imaging for monitoring the therapeutic efficacy of VEGF receptor kinase inhibitor AG-013736 in rabbit VX2 liver tumours.Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer.The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts.
P2860
Q21245704-4D995B79-9D67-4960-B7DE-2B30CA3F182EQ27001560-CEF951F2-0FB0-40C2-B502-1D11ED6299AFQ34092023-4D153FDE-7387-415A-858E-95B1E1C73981Q35753931-DDAA5D8C-D4D4-4EFB-B8D9-2C58A4034DD9Q36573248-E16EEF29-F2C5-49A6-B456-9493B0E8A4ECQ36586178-824F8CCF-5C7A-4895-8345-FDA816ABD08EQ36615993-FA18D958-2E4A-4E90-9D14-16E57E3BD116Q37093432-06BB17C4-56D3-4CFA-BA66-C8DB19178965Q37276853-BFFB9312-F992-467B-B6CA-E8CD58AD81BAQ37346912-F75FF272-B0BB-479D-AD10-F8C373FBD418Q37594384-31908F9D-0937-46AA-AD3F-929735DB861DQ37799821-8D56BB20-66B8-4695-9F46-BCC1893574C9Q37852512-19170CA9-8AD8-4860-9A78-9104E85226BDQ38130312-322CFE4E-A5CB-4354-A1F3-4E2476E3E0FFQ39413633-D8A0EC18-BAE2-488F-B746-549F8525003AQ39568663-471A75A7-15C0-4AF5-8F91-95EBC93A33A8Q41872813-8129A4AE-4BA4-409C-8A11-2CBEA532A882Q44423833-62BDBBBE-0547-4D6D-8A7D-75C905850C86Q51709008-2E209F87-9716-4D84-8DAF-C8BF1A9B25B5Q51795514-31045036-E724-41FB-9EED-BF3D36B22BEDQ54655761-5153D9D7-523A-4EBD-AF83-83B5C66ACE75
P2860
Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Dominant effect of antiangioge ...... cyclophosphamide and axitinib
@ast
Dominant effect of antiangioge ...... cyclophosphamide and axitinib
@en
type
label
Dominant effect of antiangioge ...... cyclophosphamide and axitinib
@ast
Dominant effect of antiangioge ...... cyclophosphamide and axitinib
@en
prefLabel
Dominant effect of antiangioge ...... cyclophosphamide and axitinib
@ast
Dominant effect of antiangioge ...... cyclophosphamide and axitinib
@en
P2860
P1476
Dominant effect of antiangioge ...... cyclophosphamide and axitinib
@en
P2093
P2860
P304
P356
10.1158/1078-0432.CCR-08-1174
P407
P577
2009-01-01T00:00:00Z